Xtant Medical Secures Exclusive U.S. Rights to Dilon’s HEMOBLAST Bellows
Event summary
- Xtant Medical has acquired exclusive U.S. distribution rights to Dilon’s HEMOBLAST Bellows, a hemostatic powder for surgical procedures.
- The deal includes the integration of Dilon’s 20-person U.S. sales team into Xtant’s organization.
- HEMOBLAST Bellows is the only collagen/thrombin formulation applicable for minimal, mild, and moderate bleeding types.
- Xtant plans to update its full-year 2026 financial guidance following the release of its first quarter 2026 financial results.
The big picture
This strategic partnership allows Xtant to expand its product portfolio with a unique hemostatic solution while enhancing its commercial capabilities. The integration of Dilon’s sales team is a significant move to better address the comprehensive needs of surgeons and patients, potentially increasing Xtant’s market share in the surgical solutions sector.
What we're watching
- Market Penetration
- How Xtant will leverage Dilon’s sales team to penetrate the estimated $2.0 billion global addressable market for hemostatic products.
- Financial Impact
- Whether the integration of HEMOBLAST Bellows will significantly bolster Xtant’s revenue and financial performance.
- Strategic Alignment
- The pace at which Xtant can align HEMOBLAST Bellows with its existing portfolio of orthobiologics and spinal implant systems.
Related topics